An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer
An Open-label, Multi-center Phase Ⅳ Trial to Evaluate the Efficacy and Safety of Sequential Neoadjuvant Chemotherapy With Docetaxel(Monotaxel®) After Doxorubicin Plus Cyclophosphamide Combination Chemotherapy in Locally Advanced Breast Cancer
This is a multicenter, open-label, phase IV trial to assess the efficacy and safety of
 sequential neoadjuvant chemotherapy with 4 cycles of doxorubicin/cyclophosphamide followed by
 4 cycles of docetaxel(Monotaxel®) in patients with breast cancer of ≥5cm in size or
 cytologically confirmed axillary lymph nodes metastasis.
Inclusion Criteria:

 1. Patients with histologically proven invasive breast cancer - the primary tumor size is
 at least 5cm or cytologically proven axillary node metastasis

 2. no evidence of systemic metastasis pathologically or radiologically

 3. age at the time of diagnosis between 20 and 70 years

 4. patients with previously untreated primary breast cancer including chemotherapy

 5. general performance status with ECOG 0-2

 6. sufficient hematopoietic function (absolute neutrophil count of ≥ 1,500/mm3, platelet
 count of ≥ 100,000/mm3, and hemoglobin of ≥ 10 g/dL)

 7. sufficient renal function (serum creatinine level of ≤ 1.5 mg/dL)

 8. sufficient liver function (total serum bilirubin level ≤ 1.5 times the upper normal
 limit; serum AST and ALT levels ≤ 1.5 times the upper normal limit; and serum alkaline
 phosphatase level ≤ 1.5 times the upper normal limit)

 9. sufficient cardiac function (normal electrocardiography within 1 month or LVEF>50% by
 echocardiography or MUGA scan within 3 months)

 10. patients who agree to enroll this clinical trial and sign the written informed consent
 voluntarily

 Exclusion Criteria:

 1. patients with evidence of distant metastases

 2. patients with other previous malignancy except breast cancer

 3. pregnant (positive hCG test 1 week before registration) or lactating patient

 4. uncontrolled serious infection

 5. patients with psychiatric disease or epilepsy

 6. patients with clinically severe cardiac disease within 6 months such as atrial or
 ventricular arrhythmia, congestive heart failure, myocardial infarction, or unstable
 angina

 7. male breast cancer

 8. patients with poor general condition who are not able to understand or sign the
 written informed consent